Abstract
We initiated a randomized, double-blinded, placebo-controlled trial of intravenous immunoglobulin (IVIG) treatment in myasthenia gravis (MG). Patients received IVIG 2 gm/kg at induction and 1 gm/kg after 3 weeks vs. 5% albumin placebo. The primary efficacy measurement was the change in the quantitative MG Score (QMG) at day 42. Fifteen patients were enrolled (6 to IVIG; 9 to placebo) before the study was terminated because of insufficient IVIG inventories. At day 42, there was no significant difference in primary or secondary outcome measurements between the two groups. In a subsequent 6-week open-label study of IVIG, positive trends were observed.
Original language | English (US) |
---|---|
Pages (from-to) | 549-552 |
Number of pages | 4 |
Journal | Muscle and Nerve |
Volume | 26 |
Issue number | 4 |
DOIs | |
State | Published - Oct 1 2002 |
Keywords
- Clinical trials
- Intravenous immunoglobulin
- Myasthenia gravis
- Treatment
ASJC Scopus subject areas
- Clinical Neurology
- Physiology (medical)
- Cellular and Molecular Neuroscience
- Physiology